Unresectable chemorefractory liver metastases: Radioembolization with 90Y microspheres - Safety, efficacy, and survival

Radiology

Volumn 247, Issue 2, 2008, Pages 507-515

  Sato, Kent T ^a   Lewandowski, Robert J ^a   Mulcahy, Mary F ^a   Atassi, Bassel ^a   Ryu, Robert K ^a   Gates, Vanessa L ^a,b   Nemcek Jr , Albert A ^a   Barakat, Omar ^a   Benson III, Al ^a   Mandal, Robert ^c   Talamonti, Mark ^a   Wong, Ching Yee O ^d   Miller, Frank H ^a   Newman, Steven B ^a   Shaw, John M ^a   Thurston, Kenneth G ^e   Omary, Reed A ^a   Salem, Riad ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c North Shore Oncology and Hematology Associates   (United States)

^d BEAUMONT HOSPITAL   (United States)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

BILIRUBIN; RADIOACTIVE MICROSPHERE; TUMOR MARKER; YTTRIUM 90; MICROSPHERE; YTTRIUM;

ABDOMINAL PAIN; ADULT; AGED; ANOREXIA; ARTICLE; ARTIFICIAL EMBOLISM; BILIRUBIN BLOOD LEVEL; CANCER CLASSIFICATION; CANCER LOCALIZATION; CANCER SIZE; CANCER SURVIVAL; CHILL; CLINICAL TRIAL; COLORECTAL TUMOR; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DEMOGRAPHY; DIARRHEA; DOSIMETRY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FOLLOW UP; HEMATOMA; HUMAN; INFORMED CONSENT; LIVER FUNCTION; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; NEUROENDOCRINE TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTPATIENT CARE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; TASTE DISORDER; TOXICITY; TRANSIENT GUSTATORY CHANGE; TREATMENT OUTCOME; TREATMENT RESPONSE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DISEASE COURSE; INTRAARTERIAL DRUG ADMINISTRATION; LIVER TUMOR; METASTASIS; MIDDLE AGED; SURVIVAL;

DISEASE PROGRESSION; FEMALE; HUMANS; INFUSIONS, INTRA-ARTERIAL; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MICROSPHERES; MIDDLE AGED; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TOMOGRAPHY, EMISSION-COMPUTED; TREATMENT OUTCOME; YTTRIUM RADIOISOTOPES;

EID: 44449120290     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.2472062029     Document Type: Article

References (31)

1. Andrews JC, Walker SC, Ackermann RJ, Cotton LA, Ensminger WD, Shapiro B. Hepatic radioembolization with yttrium-90 containing glass microspheres: preliminary results and clinical follow-up. J Nucl Med 1994;35(10):1637-1644.
2. Herba MJ, Illescas FF, Thirlwell MP, et al. Hepatic malignancies: improved treatment with intraarterial Y-90. Radiology 1988;169(2):311-314.
3. Herba MJ, Thirlwell MP. Radioembolization for hepatic metastases. Semin Oncol 2002;29(2):152-159.
4. Lewandowski RJ, Thurston KG, Goin JE, et al. 90Y microsphere (TheraSphere) treatment for unresectable colorectal cancer metastases of the liver: response to treatment at targeted doses of 135-150 Gy as measured by [18F] fluorodeoxyglucose positron emission tomography and computed tomographic imaging. J Vasc Interv Radiol 2005;16(12):1641-1651.
5. Carr BI. Hepatic arterial 90Yttrium glass microspheres (Therasphere) for unresectable hepatocellular carcinoma: interim safety and survival data on 65 patients. Liver Transpl 2004;10(2 suppl 1):S107-S110.
6. Georgiades CS, Salem R, Geschwind JF. Radioactive microspheres for the treatment of HCC. In: Golzarian J, ed. Vascular embolotherapy: a comprehensive approach. New York, NY: Springer, 2005; 141-148.
7. Geschwind JF, Salem R, Carr BI, et al. Yttrium-90 microspheres for the treatment of hepatocellular carcinoma. Gastroenterology 2004;127(5 suppl 1):S194-S205.
8. Liu MD, Uaje MB, Al-Ghazi MS, et al. Use of Yttrium-90 TheraSphere for the treatment of unresectable hepatocellular carcinoma. Am Surg 2004;70(11):947-953.
9. Salem R, Lewandowski RJ, Atassi B, et al. Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (TheraSphere): safety, tumor response, and survival. J Vasc Interv Radiol 2005;16(12):1627-1639.
10. Goin JE, Salem R, Carr BI, et al. Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: factors associated with liver toxicities. J Vasc Interv Radiol 2005;16(2 pt 1):205-213.
11. Goin JE, Salem R, Carr BI, et al. Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: a risk-stratification analysis. J Vasc Interv Radiol 2005;16(2 pt 1):195-203.
12. Gray B, Van Hazel G, Hope M, et al. Randomised trial of SIR-spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Ann Oncol 2001;12(12):1711-1720.
13. Gray BN, Anderson JE, Burton MA, et al. Regression of liver metastases following treatment with yttrium-90 microspheres. Aust N Z J Surg 1992;62(2):105-110.
14. Gray BN, Burton MA, Kelleher DK, Anderson J, Klemp P. Selective internal radiation (SIR) therapy for treatment of liver metastases: measurement of response rate. J Surg Oncol 1989;42(3):192-196.
15. Lau WY, Ho S, Leung TW, et al. Selective internal radiation therapy for nonresectable hepatocellular carcinoma with intraarterial infusion of 90yttrium microspheres. Int J Radiat Oncol Biol Phys 1998;40(3):583-592.
16. Lau WY, Leung WT, Ho S, et al. Treatment of inoperable hepatocellular carcinoma with intrahepatic arterial yttrium-90 microspheres: a phase I and II study. Br J Cancer 1994;70(5):994-999.
17. Salem R, Thurston KG, Carr BI, Goin JE, Geschwind JF. Yttrium-90 microspheres: radiation therapy for unresectable liver cancer. J Vasc Interv Radiol 2002;13(9 pt 2):S223-S229.
18. Salem R, Thurston KG. Radioembolization with 90Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. I. Technical and methodologic considerations. J Vasc Interv Radiol 2006;17(8):1251-1278. [Published correction appears in J Vasc Interv Radiol 2006;17(10):1594.]
19. Omary RA, Bettmann MA, Cardella JF, et al. Quality improvement guidelines for the reporting and archiving of interventional radiology procedures. J Vasc Interv Radiol 2003;14(9 pt 2):S293-S295.
20. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92(3):205-216.
21. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457.
22. Cox DR, Oaks D. Analysis of survival data. London, England: Chapman & Hall, 1984.
23. Sato K, Lewandowski RJ, Bui JT, et al. Treatment of unresectable primary and metastatic liver cancer with yttrium-90 microspheres (TheraSphere): assessment of hepatic arterial embolization. Cardiovasc Intervent Radiol 2006;29(4):522-529.
24. Wong CY, Salem R, Qing F, et al. Metabolic response after intraarterial 90Y-glass microsphere treatment for colorectal liver metastases: comparison of quantitative and visual analyses by 18F-FDG PET. J Nucl Med 2004;45(11):1892- 1897.
25. Salem R, Lewandowski R, Roberts C, et al. Use of Yttrium-90 glass microspheres (TheraSphere) for the treatment of unresectable hepatocellular carcinoma in patients with portal vein thrombosis. J Vasc Interv Radiol 2004;15(4):335-345.
26. Kulik LM, Atassi B, van Holsbeeck L, et al. Yttrium-90 microspheres (TheraSphere) treatment of unresectable hepatocellular carcinoma: downstaging to resection, RFA and bridge to transplantation. J Surg Oncol 2006;94(7):572-586.
27. Cunningham D, Pyrhonen S, James RD, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998;352(9138):1413-1418.
28. Ercolani G, Grazi GL, Ravaioli M, et al. The role of liver resections for noncolorectal, nonneuroendocrine metastases: experience with 142 observed cases. Ann Surg Oncol 2005;12(6):459-466.
29. Harrison LE, Brennan MF, Newman E, et al. Hepatic resection for noncolorectal, nonneuroendocrine metastases: a fifteen-year experience with ninety-six patients. Surgery 1997;121(6):625-632.
30. Schwartz SI. Hepatic resection for noncolorectal nonneuroendocrine metastases. World J Surg 1995;19(1):72-75.
31. Weitz J, Blumgart LH, Fong Y, et al. Partial hepatectomy for metastases from noncolorectal, nonneuroendocrine carcinoma. Ann Surg 2005;241(2):269-276.